<DOC>
	<DOCNO>NCT00366782</DOCNO>
	<brief_summary>Human parainfluenza virus ( HPIVs ) major health concern infant young child 5 year age , cause serious respiratory tract disease . The purpose study test safety immune response new HPIV vaccine healthy infant , child , adult .</brief_summary>
	<brief_title>Safety Immune Response Cow/Human Parainfluenza Virus Vaccine ( rB/HPIV3 ) Healthy Infants , Children , Adults</brief_title>
	<detailed_description>HPIV type 3 ( HPIV3 ) rank second respiratory syncytial virus common cause bronchiolitis pneumonia infant less 6 month age . HPIV3 cause severe disease first 2 year life responsible 11 % hospitalization respiratory diseases child . This study evaluate safety immunogenicity live , chimeric bovine/human , attenuate intranasal HPIV3 vaccine , rB/HPIV3 . This vaccine combine modify human HPIV3 relate , modify cow virus , bovine parainfluenza type 3 virus ( BPIV3 ) . Vaccinations give nose drop healthy adult , child seropositive HPIV3 , infants child seronegative HPIV3 . There four group study . Group 1 consist adult receive high dose rB/HPIV3 . Group 2 consist seropositive child randomly assign receive high dose rB/HPIV3 placebo . Group 2 begin enrollment completion Group 1 safety data review . Participants Groups 1 2 monitor 10 day post vaccination respiratory illness fever self-reported temperature log ; participant follow maximum 28 day . Blood collection occur study entry Day 28 ; additional blood collection may occur 28 day prior vaccination . Clinical assessment nasal wash occur study entry select study visit . Group 1 participant contact phone Day 180 ; Group 2 participant ' parent guardian contact phone Days 1 , 2 , 8 , 9 , 11 , 180 ; study staff ask illnesses adverse event may occur . Groups 3 4 consist seronegative infant child . Group 3 begin enrollment completion Group 2 safety data review . Children Group 3 randomly assign receive low dose rB/HPIV3 placebo . Group 4 begin enrollment completion Group 3 safety data review . Children Group 4 randomly assign receive high dose rB/HPIV3 placebo . Participants Groups 3 4 monitor closely 28 day postvaccination respiratory illness fever self-reported temperature log ; participant follow maximum 56 day . Blood collection occur study entry Day 56 . Clinical assessment nasal wash occur study entry study visit . Participants ' parent guardian contact phone periodically post vaccination ; study staff ask illnesses adverse event may observe infant child .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Paramyxoviridae Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Adult Participants : Good general health Available duration trial Reachable telephone postvaccination contact Female participant willing use acceptable method contraception Inclusion Criteria Seropositive Child Participants : Good general health ageappropriate development , determine physical exam medical history review Seropositive human parainfluenza type 3 virus ( HPIV3 ) , define serum hemagglutinationinhibition ( HI ) antibody titer 1:8 Available duration trial Parent guardian willing provide inform consent Parent guardian reachable telephone postvaccination contact Inclusion Criteria Seronegative Infant Child Participants : Good general health ageappropriate development , determine physical exam medical history review Seronegative HPIV3 , define serum HI antibody titer 1:8 less within 28 day first vaccination Available duration trial Parent guardian willing provide inform consent Parent guardian reachable telephone postvaccination contact Exclusion Criteria Adult Participants : Clinically significant neurologic , heart , lung , liver , rheumatologic , autoimmune , kidney disease Behavioral , cognitive , psychiatric disease , opinion investigator , affect ability participant understand cooperate study Medical , workrelated , family problem result alcohol illicit drug use 12 month prior study entry History severe allergic reaction anaphylaxis Absence spleen Diagnosis asthma within 2 year prior study entry HIV1 infect Hepatitis C virus infect Positive hepatitis B surface antigen ( HBsAg ) Abnormal blood urine test Known immunodeficiency syndrome Blood product , include immunoglobulin , within 3 month prior study entry Immune globulin within 3 month vaccination Current smoker unwilling stop smoking duration study Participation another investigational vaccine drug trial within 30 day vaccination participate study Live vaccine within 4 week vaccination Killed vaccine within 2 week vaccination Previous immunization PIV3 vaccine Known hypersensitivity vaccine component Other condition , opinion investigator , would affect participant 's participation study Work and/or personal responsibility involve care child less 6 month age immunosuppressed individual Pregnancy breastfeed Exclusion Criteria Infant All Child Participants : Known suspected impairment immune system , include maternal history positive HIV test , previous receipt immunosuppressive therapy include systemic corticosteroid , receipt bone marrow/solid organ . Participants receive topical steroid exclude . Major congenital malformation , include congenital cleft palate , cytogenetic abnormality , serious chronic disorder Previous immunization PIV3 vaccine Previous serious vaccineassociated adverse event anaphylactic reaction Lung heart disease , include reactive airway disease . Participants clinically insignificant cardiac abnormality require treatment exclude . More information criterion find protocol . Clinically significant abnormality liver function test ( seropositive participant ) Clinically significant abnormality complete blood count ( CBC ) ( seronegative participant ) Member household include pregnant woman , immunocompromised individual , infant le 6 month age Attends day care infant less 6 month age , pregnant caregiver , immunosuppressed individual Parent guardian unwilling suspend day care 14 day follow vaccination . More information criterion find protocol . Participation another investigational vaccine drug trial within 30 day first vaccination participate study</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Respiratory Tract Disease</keyword>
	<keyword>Bovine</keyword>
	<keyword>Chimeric Vaccine</keyword>
</DOC>